Intercept Pharmaceuticals, Inc.
ICPT · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.33 | 0.25 | -0.11 | 0.06 |
| FCF Yield | 2.15% | -5.07% | -9.22% | -0.88% |
| EV / EBITDA | 174.10 | 603.78 | -31.35 | -53.83 |
| Quality | ||||
| ROIC | -1.53% | -1.75% | -7.22% | -4.36% |
| Gross Margin | 99.78% | 99.78% | 99.67% | 99.96% |
| Cash Conversion Ratio | -6.05 | 4.00 | 1.62 | 0.28 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.57% | -3.50% | -2.90% | 0.26% |
| Free Cash Flow Growth | 171.25% | 54.65% | -1,044.31% | 73.35% |
| Safety | ||||
| Net Debt / EBITDA | 23.54 | 180.74 | -10.25 | -19.15 |
| Interest Coverage | -2.98 | -2.53 | -11.26 | -6.74 |
| Efficiency | ||||
| Inventory Turnover | 0.07 | 0.03 | 0.03 | 0.00 |
| Cash Conversion Cycle | -3,447.38 | 3,041.92 | -2,509.09 | -44,143.17 |